Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) Stock-Based Compensation
The stock-based comp for Labcorp Holdings Inc. (LH) is $125.80 Million with a year-over-year change of +7.80%. Stock-Based Compensation (SBC) is the expense recognized for equity awards (stock options, RSUs) granted to employees. It's a non-cash expense that dilutes existing shareholders.
LH Stock-Based Comp Chart
LH Stock-Based Comp
$125.80M
Zoom
Current Stock-Based Comp
$125.80M
$125.80 Million
Year-over-Year Change
+7.80%
vs. $116.70M prior year
Historical Data
30
Years of data available
Annual Stock-Based Comp History
| Year | Stock-Based Comp | YoY Change | % Change |
|---|---|---|---|
| 2025 | $125.80M | +$9.10M | +7.80% |
| 2024 | $116.70M | $-12.00M | -9.32% |
| 2023 | $128.70M | +$11.90M | +10.19% |
| 2022 | $116.80M | $-16.10M | -12.11% |
| 2021 | $132.90M | +$21.20M | +18.98% |
| 2020 | $111.70M | +$4.70M | +4.39% |
| 2019 | $107.00M | +$15.40M | +16.81% |
| 2018 | $91.60M | $-18.10M | -16.50% |
| 2017 | $109.70M | +$100,000 | +0.09% |
| 2016 | $109.60M | +$7.50M | +7.35% |
| 2015 | $102.10M | +$56.40M | +123.41% |
| 2014 | $45.70M | +$8.40M | +22.52% |
| 2013 | $37.30M | $-3.40M | -8.35% |
| 2012 | $40.70M | $-8.20M | -16.77% |
| 2011 | $48.90M | +$8.90M | +22.25% |
| 2010 | $40.00M | +$3.60M | +9.89% |
| 2009 | $36.40M | +$200,000 | +0.55% |
| 2008 | $36.20M | +$36.20M | — |
| 2007 | $0 | $-52.70M | -100.00% |
| 2006 | $52.70M | +$52.70M | — |
| 2005 | $0 | +$0 | — |
| 2004 | $0 | +$0 | — |
| 2003 | $0 | +$0 | — |
| 2002 | $0 | +$0 | — |
| 2001 | $0 | +$0 | — |
| 2000 | $0 | +$0 | — |
| 1999 | $0 | +$0 | — |
| 1998 | $0 | +$0 | — |
| 1997 | $0 | +$0 | — |
| 1996 | $0 | — | — |
Related Metrics
Data as of Sunday, June 14, 2026
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter